MacroGenics (NASDAQ:MGNX) Posts Earnings Results, Misses Expectations By $0.02 EPS

MacroGenics (NASDAQ:MGNX) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02), Zacks reports. The business had revenue of $49.40 million during the quarter, compared to the consensus estimate of $34.17 million. MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%.

MacroGenics Stock Performance

Shares of MGNX opened at $2.06 on Friday. The firm has a 50 day moving average price of $2.68 and a 200-day moving average price of $3.23. MacroGenics has a fifty-two week low of $2.03 and a fifty-two week high of $19.54. The firm has a market cap of $128.98 million, a price-to-earnings ratio of -1.29 and a beta of 2.12.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.